RESPONSE OF CI-991 IN PATIENTS WITH NONINSULIN-DEPENDENT DIABETES MELLITUS

CI-991 对非胰岛素依赖型糖尿病患者的反应

• 批准号: 3761439
• 负责人: KWAME OSEI
• 金额: --
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3761439
• 关键词: clinical trials; diabetes mellitus therapy; dosage; drug adverse effect; drug screening /evaluation; endocrine disorder chemotherapy; human subject; human therapy evaluation; hypoglycemic agents; noninsulin dependent diabetes mellitus; pharmacokinetics; placebos; quality of life

The objective of this study is to identify the therapeutically useful dose range of C-991 when compared with placebo in patients with diabetes mellitus NIDDM. This study will also provide additional safety and tolerance, pharmacokinetic and quality of life information from patients treated with CI-991 for 12 weeks.

本研究的目的是确定治疗上有用的 糖尿病患者中C-991与安慰剂相比的剂量范围 NIDDM。 这项研究还将提供额外的安全性， 患者的耐受性、药代动力学和生活质量信息 用CI-991治疗12周。